timothy sykes logo

Stock News

Cidara Therapeutics: Unexpected Surge or Timely Investment?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 10/27/2025, 2:32 pm ET 10/27/2025, 2:32 pm ET | 5 min 5 min read
Cidara Therapeutics: Unexpected Surge or Timely Investment? Thumbnail

Cidara Therapeutics Inc. stocks have been trading up by 9.04 percent, driven by FDA designations and promising trial results.

Candlestick Chart

Live Update At 14:31:56 EST: On Monday, October 27, 2025 Cidara Therapeutics Inc. stock [NASDAQ: CDTX] is trending up by 9.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

A Glimpse into Cidara’s Recent Financial Health

Timothy Sykes is well-known in the world of penny stock trading. He emphasizes the importance of smart trading decisions and risk management. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This principle is crucial for traders who are navigating the volatile and unpredictable nature of the stock market. By maintaining focus on preserving your current capital, traders can enhance their chances of achieving sustainable long-term success in their trading endeavors.

Looking over Cidara Therapeutics Inc.’s latest financial reveals, the focus comes to earnings and their implications in the market. With the company bringing in $1.28M, the revenue per share stood at a low 0.05, revealing a challenging landscape in terms of sales generation. Despite these figures, recent 2025 news suggests optimism. The removal of $24.72M from their net income speaks volumes about the hurdles they face in turning a profit, which translates to a diluted EPS of -$1.65, reflecting significant ongoing operational costs.

The spotlight brightens when considering their total assets of $534.33M. However, the liabilities sum up to a sound $33.15M. The enterprise value sits around $1.85B, signaling investor interest, albeit with cautious overtones. Statistical ratios show a high price-to-sales at 1,852.03, casting light on an arguably overvalued situation considering their revenue. Yet, with a solid quick ratio of 15.9, Cidara shows stability in covering short-term liabilities, giving them ample breathing room.

Exploring the Effect of Recent News Articles on CDTX

Recent news heavily covers the influence of CD388, drawing a tapestry of future expectations for Cidara. The market scuttlebutt revolves around CD388, receiving both a Breakthrough Therapy designation from the FDA and a substantial BARDA contract backing. This leaves prospects favorable, as CD388 progresses – its value for preventing flu in high-risk individuals remains high. Not stopping there, CD388 marks another accomplishment with H.C. Wainwright hiking its price target from $153 to $173. Having it perceived as a game-changer elevates its status immensely.

The media waves reflect the optimism seen in stock price momentum, leading Cidara to financial markets’ forefront. Recent updates highlight clinical presentations, a nod to the translation of pre-clinical to clinical success, evoking an aura of predictable success.

The surging mentions of CD388’s ground-breaking potential can likely lead to speculative buys, momentarily boosting stock prices. However, long-term gains hinge on CD388 consistently delivering clinically. Short-term investors may see these news reports as an attractive entry point but should remain cautious of pumps led by speculative potential.

More Breaking News

Summary: Highlighting Influential News

Cidara’s narrative is crafted by significant advancements paired with strategic wins. CD388 appears as a talisman, inseparable from current market sentiment towards Cidara’s deliverables. The contract hailed by BARDA injects confidence, but market players should stay wary of expectations overflow. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Panning out, the trail SRVival takes depends on CD388 converting promise into tangible returns. Inextricably, speculation and clinical evolution remain locked in tandem, determining the next move of CDTX, amidst talk of highs and an intriguing—for some promising—trading journey. Time shall reveal whether expectations spring eternal or if nuances cast shadows on idealistic stock values.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”